Mba14lob Sec- c a1 Mehboob

8/6/2019 Mba14lob Sec- c a1 Mehboob

1/5

LEADERSHIP AND ORGANIZATIONAL BEHAVIOR

ASSIGMENT 1

1

BMA- MEHBOOB ELAHI LASKAR

INTRODUCTION:

Personality is the supreme realization of the innate idiosyncrasy of a living being. It is an act of

high courage flung in the face of life, the absolute affirmation of all that constitutes the

individual, the most successful adaption to the universal condition of existence coupled with the

greatest possible freedom for self-determination.

Carl Gustav Jun, 1994

The word personality is derives from the Latin word persona which means mask. The study

of personality can be understood as the study of mask that people wear. These are the personas

that people project and display, but also include the inner parts of psychological experience

which we collectively call our selfIt is an attempt to capture or summarize an individuals essence. Personality is person-ality, the

science of describing and understanding person.

No two people are exactly the same- not even identical twins. Some people are anxious, some are

risk taking, some are unconcerned, some highly-stung, some are confident, some shy, and some

are quiet and some are loquacious. This issue of difference is fundamental to the study of

personality

Literature Review:

Dr. Kiran Mazumdar-Shaw, Founder and CMD, Biocon Group, Bangalor.

Biocon is research driven, global healthcare company with a strong matrix of capabilities along

the biopharmaceutical value chain. Biocon is indias leading biotechnology enterprise observant

on the development of biopharmaceuticals. Biocon has evolved from an enzyme manufacturing

company to a fully integrated biopharmaceutical enterprise, focused on health care. Biocon has

effectively forayed into drug discovery and development. It has developed effective and

innovative bimolecular in diabetology, oncology, cardiology and other segments. Biocon


2/5


ASSIGMENT 1

2


delivers products and solution to partners and customers in more than 50 countries. There are

other subsidiary companies of Biocon like

Syngene International Ltd. is a custom research organization offering synthetic chemistry and

molecular biology services for early stage drug discovery and development.

Clinigene International Ltd. is a clinical research organization offering phase I-IV clinical trials

and studies for generic molecules to international pharmaceutical majors.

Biocon Biopharmaceuticals private ltd is a joint venture with CIMAB to develop and market a

range of monoclonal antibodies and cancer vaccines

AxiCorp GmbH is a friedrichsdorf(Germany) based pharmaceutical marketing company and is

amongst the fastest growing in Europe. Biocon Limited acquired a majority stake in AxiCrop

GmbH(70%) in feb,2008.

Kiran Mazumdar- Shaw

Chairman & Managing Director- Biocon

Our ability to continuously scale new heights across the biopharmaceutical value chain enables

us to realize the promise of future therapeutics.

Kiran Mazumder Shaw was born on March 23, 1953 in Bangalore. She had her schooling at

Bishop Cotton Girls School and Mount Carmel College at Bangalore. After completing her B.Sc.

in Zoology from Bangalore University in 1973, she went to Ballarat University in Melbourne,

Australia to pursue her further studies and got herself qualified as a master brewer.

She started her professional career as a trainee brewer in Carlton & United Beverage in 1974; she

joined as a trainee manager with Biocon Biochemical Ltd. in Ireland. In the same year Kiran

Mazumder Shaw founded Biocon India in collaboration with Biocon Biochemical Ltd. with a

capital of Rs 10,000. She initially faced many problems regarding funds for her business.

Especially banks were very hesitant to give loan to her as biotechnology was totally a new field


3/5


ASSIGMENT 1

3


at that point of time and moreover she was a woman entrepreneur, which was a rare phenomenon

at that time.

Biocons initial operation was to extract an enzyme from papaya. Under her stewardship Biocon

transformed from an industrial enzymes company to an integrated bio-pharmaceutical company

with strategic research initiatives. Today, Biocon is recognized as Indias pioneering biotech

enterprise. In 2004, Biocon came up with an IPO and the issue was over-subscriebed by over 30

times. Post-IPO, she shaw held close to 40% of the stock of the company and was regarded as

Indias richest woman with an estimated worth of Rs. 2100 crore.

She is the recipient of several prestigious awards. These include ET businesswoman of the year,

Best Woman Entrepreneur, Model Employer, Ernst & Youngs Entrepreneur of the year Award

for life Sciences & Healthcare, Leading Exporter, Outstanding Citizen, Technology Pioneer, etc.

she was given important positions in Industry Councils as well, including Vice-President,

Association of Women Entrepreneur of Karnataka. She was awarded Rotary Award for Best

Model Employer, National for Best Small Industry. And most note worthily, the Padmashri in

1989 and Padma Bhushan in 2005 from the Gvt of India.

Her vision for the future is to grow into a global bio-therapeutics company with very innovative

and proprietary products and technologies.

ANALYSIS AND JUSTIFICATION;

Biocon was founded on November 29, 1978 as a joint venture between Bicon Biochemicals Ltd.

of Ireland and an Indian entrepreneur, Kiran Mazumdar Shaw. In 1978, Biocon became the first

Indian company to manufacture and export enzymes to USA and Europe. Unilever plc. acquired

Biocon Biochemical Ltd. in Ireland in 1979 and merged it with its subsidiary, Quest

International. In 1989, Biocon become the first Indian biotech company to receive US funding

for proprietary technologies. In 1983, Biocons R&D and manufacturing facilities received

ISO9001 certificate from RWTUV, Germany. In 1994, Biocon established a subsidiary Syngene

International Pvt. Ltd to address to growing need of outsourced R&D in pharmaceutical sector.

In 1996, Biocon entered in the biopharmaceutical segment. In 1998, Unilever sold its


4/5


ASSIGMENT 1

4


shareholding in Biocon to the Indian promoter and Biocon become an independent entity. In

2000 Biocon commissioned its first fully automated submerged fermentation plant to produce

specialty pharmaceuticals. In 2001 Biocon became the first Indian company to be approved by

US FDA for the manufacture of lovastatin, a cholesterol lowering molecule. In 2003 Biocon

became the first company worldwide develop human insulin on a Phchia expression system. In

2004 it entered the stock market with its IPO and became only second Indian company to cross

the $1 billion mark on the day of listing. In 2006 it has launched Indias first cancer BIOMAb

EGFR. Biocon announces a licensing agreement with Bayer Health Care for the exclusive

marketing and trademark rights for INSUGEN for Chinese market.

Syngene and Innate pharmaceuticals AB, Umea, Sweden conclude a cooperation agreement to

jointly develop, manufacture and market virulence blockers to counteract bacterial diarrhoealdisease.

In 2007 Biocon announces the launch of its Nephrology Division and a comprehensive portfolio

of renal therapy products.

CONCLUSION:

From my point of view personality is way in which an individual react to and interact with

others. Dr. kiran Mazumder Shaw is a very successful woman entrepreneur and she is very much

hardworking because of which her company is Indias leading bio-technology company. She has

introduced biotechnology to India. She is very ambitious, aggressive. She is extraverted kind of

individual as she is outgoing, sociable and confident. Moreover she shows some resemble of

Type A Personality as she is very aggressive, risk taking, self monitoring.


5/5


ASSIGMENT 1

5


Bibliographybhargava, p. m. (2003, 02 10).google. Retrieved 09 2009, 2009, from biospectrumindia:

http://biospectrumindia.ciol.com/content/future/10302101.asp

biocon. (2009, 09 01). Retrieved 09 02, 2009, from biocon: http://www.biocon_aboutus_history.asp.htm

Biocon chief tops poll of biotech personalities outside US, Europe. (2006, 03 10). Retrieved 09 02, 2009,

from thehindubusinesslinne.com:

http://www.thehindubusinessline.com/2006/03/10/stories/2006031003290800.htm

Biocon unveils long play insulin Basalog. (2009, 05 30). Retrieved 09 2, 2009, from

thehindubusinessline: http://www.thehindubusinessline.com/2009/05/30/stories/2009053050760300.htm

Biocon unveils long play insulin Basalog. (2009, 03 30). Retrieved 09 2, 2009, from

thehindubusinessline: www.hindubusinessline.com/2009053050760300.htm

bioconindia. (2007, 07 21). Retrieved 09 2, 2009, from iloveindia: ttp://www.iloveindia.com/economy-of-

india/top-50-companies/biocon.html

dheeraj. (2008, 12 07). theceoinsights. Retrieved 09 2, 2009, from theceiinsights.com:

http://www.theceoinsights.com

governing body. (n.d.). Retrieved 09 02, 2009, from ibab.com:

http://www.ibab.ac.in/abt_governing_body.htm

indian pharmaceutica industryl overview. (n.d.). Retrieved 09 2, 2009, from pharmaceutical-drug-

manufacturers.com: http://www.pharmaceutical-drug-manufacturers.com/pharmaceutical-industry/

The Scope of Biotechnology: the Indian Advantage. (2003, 02 10). Retrieved 09 02, 2009, frombiospectrum: http://biospectrumindia.ciol.com/content/future/10302101.asp

Carver, C. S., & Scheier, M. F. (2000). Perspectives on personality (4th ed.) Boston: Allyn and Bacon.

Burger, J. M. (1993). Personality (3rd ed.) Pacific Grove, CA: Brooks/Cole.

Ridley, M (1999). Genome: The autobiography of a species in 23 chapters. London: Fourth Estate.

Schultz, D., & Schultz, S.E. (1994). Theories of personality (5th ed.) Pacific Grove, CA: Brooks/Cole

Documents

Mba14lob Sec- c a1 Mehboob